18F-FDG PET/CT在弥漫大B细胞淋巴瘤不同治疗节点评估疗效与预后价值的研究
该回顾性研究纳入127例弥漫大B细胞淋巴瘤患者,再评估基线、中期(3-4周期后)及治疗结束(6-8周期后)的18F-FDG PET/CT,采用Deauville 5点评分及SUVmax(LLR)、SUVmax(LMR)、TMTV、TLG等半定量参数。中位随访34个月,中期PET视觉分析联合半定量参数可提高预后预测准确性,有助于筛选需早期强化治疗的患者。
要点
- 中期PET视觉分析不完全代谢缓解与进展和死亡风险增加相关。
- ΔSUVmax(LLR)1<89.2%、ΔTMTV1<91.8%、ΔTLG1<98.8%、ΔSUVmax(LLR)2<86.4%与PFS缩短显著相关。
- 中期PET视觉分析与半定量参数联合较单一指标预测复发具有更高阳性预测值和特异性。
核心结论
- 3-4周期R-CHOP治疗可能是早期预测早期复发/难治(R/R)患者并积极抢先治疗的时间点。
- 中期18F-FDG PET/CT视觉分析与半定量参数联合可提高预后准确性,可能有助于更精准筛选需要早期强化治疗的患者。
研究设计与样本
- 回顾性分析127例DLBCL患者(男62例,女65例,中位年龄62岁)。
- 基线PET/CT 127例,中期PET/CT 127例(3-4周期后),治疗结束PET/CT 53例(6-8周期后),均重新评估。
- 记录SUVmax(LLR)、SUVmax(LMR)、TMTV、TLG等半定量参数,并以Deauville 5点评分(D-5PS)作为PET评估主要标准。
- 采用Kaplan-Meier法、Cox回归和logistic回归分析视觉分析与半定量参数预测无进展生存(PFS)和总生存(OS)的能力。
- 视觉分析与半定量分析联合时,两者均阳性才判定为阳性。
主要发现
- 中位随访34个月,中位PFS为20个月,中位OS为32个月。
- 晚期分期和IPI评分预后不良、ΔSUVmax(LLR)1<89.2%、ΔTMTV1<91.8%、ΔTLG1<98.8%、ΔSUVmax(LLR)2<86.4%与患者PFS缩短显著相关(p<0.05)。
- ΔSUVmax(LLR)1<83.2%和ΔTLG1<97.6%与患者OS缩短显著相关(p<0.05)。
- 视觉分析显示中期PET和结束PET不完全代谢缓解增加进展和死亡风险。
- 中期PET预测复发方面,视觉与半定量参数联合较单一指标显示更高阳性预测值和特异性。
关键数值与推荐
- 以Deauville 5点评分(D-5PS)作为PET评估的主要标准。
- ΔSUVmax(LLR)1<89.2%、ΔTMTV1<91.8%、ΔTLG1<98.8%、ΔSUVmax(LLR)2<86.4%与PFS缩短显著相关(p<0.05)。
- ΔSUVmax(LLR)1<83.2%和ΔTLG1<97.6%与OS缩短显著相关(p<0.05)。
临床怎么用
- 3-4周期R-CHOP治疗可能是早期预测早期复发/难治患者并积极抢先治疗的时间点。
- 中期18F-FDG PET/CT视觉分析与半定量参数联合可提高预后准确性,可能有助于更精准筛选需要早期强化治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the present study, we aimed to investigate the role of baseline (B), interim (I) and end-of-treatment (Eot) 18F-FDG PET/CT in assessing the prognosis of diffuse large B cell lymphoma (DLBCL), so as to identify patients who need intensive treatment at an early stage. METHODS: A total of 127 DLBCL patients (62 men; 65 women; median age 62 years) were retrospectively analyzed in this study. Baseline (n = 127), interim (n = 127, after 3-4 cycles) and end-of-treatment (n = 53, after 6-8 cycles) PET/CT images were re-evaluated; semi-quantitative parameters such as maximum standardized uptake value of lesion-to-liver ratio (SUVmax(LLR)) and lesion-to-mediastinum ratio (SUVmax(LMR)), total metabolic tumor volume (TMTV) and total metabolic tumor volume (TLG) were recorded. ΔTLG1 was the change of interim relative to baseline TLG (I to B), ΔTLG2 (Eot to B). ΔSUVmax and ΔTMTV were the same algorithm. The visual Deauville 5-point scale (D-5PS) has been adopted as the major criterion for PET evaluation. Visual analysis (VA) and semi-quantitative parameters were assessed for the ability to predict progression-free survival (PFS) and overall survival (OS) by using Kaplan-Meier method, cox regression and logistic regression analysis. When visual and semi-quantitative analysis are combined, the result is only positive if both are positive. RESULTS: At a median follow-up of 34 months, the median PFS and OS were 20 and 32 months. The survival curve analysis showed that advanced stage and IPI score with poor prognosis, ΔSUVmax(LLR)1 < 89.2%, ΔTMTV1 < 91.8% and ΔTLG1 < 98.8%, ΔSUVmax(LLR)2 < 86.4% were significantly related to the shortening of PFS in patient (p < 0.05). ΔSUVmax(LLR)1 < 83.2% and ΔTLG1 < 97.6% were significantly correlated with the shortening of OS in patients (p < 0.05). Visual analysis showed that incomplete metabolic remission at I-PET and Eot-PET increased the risk of progress and death. In terms of predicting recurrence by I-PET, the combination of visual and semi-quantitative parameters showed higher positive predictive value (PPV) and specificity than a single index. CONCLUSION: Three to four cycles of R-CHOP treatment may be a time point for early prediction of early recurrence/refractory (R/R) patients and active preemptive treatment. Combined visual analysis with semi-quantitative parameters of 18F-FDG PET/CT at interim can improve prognostic accuracy and may allow for more precise screening of patients requiring early intensive therapy.
引用
- Zhao W, Wu X, Huang S, et al. Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients. EJNMMI Res. 2024. PMID: 38372908. doi:10.1186/s13550-024-01074-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。